LAM Extra for General Practicioners - 2012;4(01)

LAM Extra for General Practicioners

FEBRUARY 20, 2012

[PAIN MANAGEMENT IN RHEUMATOLOGY]

NAGY Katalin

[Pain is the most common symptom in rheumatology, which can be of mechanical or inflammatory origin, acute and chronic, nociceptive, neuropathic and psychogenic. Pain can be relieved by analgesics, nonsteroidal anti-inflammatory drugs, opioids, adjuvants and special drugs depending on the etiology, for example a gout attack can be stopped by colchicine. For pain relief, we use therapeutic guidelines of the World Health Organization (WHO), which recommends the use of analgesics, NSAIDs and... tovább »

LAM Extra for General Practicioners

FEBRUARY 20, 2012

[PYCNOGENOL IN THE CLINICAL PRACTICE]

KISS István, TAVASZY Mariann, FARSANG Csaba

[Polyphenols, which belong to the group of flavonoids, can be found in a number of plants, and are present in a high concentration in the French maritime pine bark. The authors summarise results of large-scale experimental and clinical studies on pycnogenol, the standardised extract of French maritime pine bark. Pycnogenol decreases production and effects of free radicals (antioxidant effect). It has antiinflammatory properties, and, by the stimulation of eNOSsynthesis, it increases the... tovább »

LAM Extra for General Practicioners

FEBRUARY 20, 2012

[ANTIDIABETIC THERAPY OF PATIENTS WITH TYPE 2 DIABETES - THE PLACE OF ADMINISTRATION OF ACARBOSE]

KEMPLER Péter

[Administration of the alpha-glucosidase enzyme inhibitor acarbose leads to a prolonged absorption of carbohydrates, which has a smoothing effect on blood glucose excursions, and results in a more even daily blood glucose profile. The glucose lowering effect is mainly due to the reduction of postprandial blood glucose levels. Non-glycaemic effects of acarbose, including those on blood pressure, lipids and the coagulation system are also clearly beneficial. According to the available data, the... tovább »

LAM Extra for General Practicioners

FEBRUARY 20, 2012

[HOW DIABETOGENIC IS STATIN THERAPY?]

CSÁSZÁR Albert

[According to the latest guidelines, the goal in cardiovascular prevention is to achieve an LDL-cholesterol level no higher than 1.8 mmol/l in the high risk and extra high risk groups. According to international recommendations, statin should be used at the highest tolerable dose rather than any combination treatments. In a number of cases, higher doses are associated with increased side effects, which rarely affect liver enzymes and CK-parameters. A metaanalysis published in 2011 made it clear... tovább »

LAM Extra for General Practicioners

FEBRUARY 20, 2012